Phathom Q3 net revenues $16.4M, up >120% QoQ; net loss $85.6M; VOQUEZNA prescriptions exceed 143k launch-to-date

Phathom Pharmaceuticals, Inc.

2024-Q3 EPS reported -$4.29 revenue$25,588,000

Net revenues $16.4M for Q3 2024 (vs $7.3M Q2 2024); no revenues in Q3 2023.
Over 143,000 prescriptions for VOQUEZNA products filled launch-to-date (138% increase since last quarterly report).
Net loss $85.6M vs $43.2M in Q3 2023; non-GAAP adjusted net loss $67.9M vs $30.8M.
Commercial access expanded to >80% of U.S. commercial lives (est. 120M covered lives).
R&D expenses down to $8.7M; SG&A up to $76.1M due to commercial buildout.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.